Quidditas Therapeutics

Executive Summary

Quidditas Therapeutics is a Belgian biotechnology company founded in 2021, based in Leuven, focused on developing a novel genome editing technology named GREAT (Genetic Recombination for Excision And Therapy). This technology enables 'absolute genetic recombination' and aims to overcome limitations of current editing tools such as CRISPR, particularly in terms of precision, efficiency, and safety. The company's initial therapeutic applications target neuroscience and rare genetic disorders, areas of high unmet medical need where precise genetic correction could offer transformative benefits. Quidditas' platform has broader potential across multiple sectors, positioning it as a versatile player in the gene editing landscape. As a private, early-stage company, Quidditas Therapeutics has not yet disclosed funding rounds or clinical milestones. The company's progress will depend on securing financing for preclinical development and validating its GREAT technology in relevant disease models. While the concept of absolute recombination is promising, the field of gene editing is highly competitive, with established players like CRISPR Therapeutics and Intellia. Quidditas' success hinges on demonstrating superior outcomes in terms of editing fidelity and delivery. Near-term catalysts could include seed or Series A funding, initial preclinical data, and strategic partnerships to advance its pipeline.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round60% success
• Q2 2026Preclinical Proof-of-Concept Data Release40% success
• Q4 2026Research Partnership with Academic Institution30% success